Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13

Authors:
  • JWJames R. Wright
    James R. Wright
  • RSR. Suzanne Swann
    R. Suzanne Swann
  • FNFelix Nguyen-Tân
    Felix Nguyen-Tân
  • CTCristiane Takita
    Cristiane Takita
  • MBM. Kara Bucci
    M. Kara Bucci
  • HKHarold Kim
    Harold Kim
  • EHEugen B. Hug
    Eugen B. Hug
  • JRJanice Ryu
    Janice Ryu
  • MGMichael Greenberg
    Michael Greenberg
  • JSJerrold P. Saxton
    Jerrold P. Saxton
Publisher website
Google Scholar
Abstract
Purpose This multicentered phase III trial was designed to compare an emulsion containing trolamine against the usual supportive care within each participating institution for patients with head and neck cancer undergoing radiation therapy. Patients and Methods Patients with biopsy-proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx were randomly assigned to one of the following treatments: prophylactic trolamine emulsion, interventional trolamine emulsion, or declared institutional preference. The primary outcome was the reduction in grade 2 or higher skin toxicity, as per National Cancer Institute Common Toxicity Criteria version 2.0. Secondary outcomes included patient-reported quality of life (QOL). Results From October 2000 to April 2002, 547 patients from 51 institutions were entered onto the trial. The average age was 59 years. Patients were predominately male (79%) and most continued to use tobacco products (52%). The rates of grade 2 or higher radiation dermatitis were 79%, 77%, and 79% in the prophylactic, interventional, and institutional preference arms of the study, respectively. No significant differences in QOL were found. Conclusion The results of this trial demonstrate no advantage for the use of trolamine in reducing the incidence of grade 2 or higher radiation dermatitis or improving patient-reported QOL. The use of 15 different local standards of care highlights the need to continue research that will result in evidence-based recommendations to reduce the burden of radiation dermatitis.

This publication has 16 references indexed in Scilit: